Latin America QuickFire Challenge
Challenge ended
Residency at JLABS
Therapeutics
Winners
Focused on the production of recombinant proteins from the Zika virus capsid that could be used for isolating or developing anti-Zika monoclonal antibodies, which may be used to treat or reduce the viral load of infected individuals.
The Challenge
As part of the innovation forum for Latin America, Johnson & Johnson Innovation has committed to award one new game-changing early-stage innovation company from Latin America access to the Johnson & Johnson Innovation, JLABS community for six months through participation in a QuickFire Challenge. The JLABS QuickFire Challenge for Latin America is to support ideas to trigger health innovation from the Latin America region.